Cellectis SA

20-F13D

Schedule 13D - Activist Investments

NASDAQ
CLLS
Cellectis SA
SCHEDULE: Bpifrance Group Adjusts Cellectis S.A. Ownership Stake
Bpifrance and Caisse des Depots group's beneficial ownership percentage in Cellectis S.A. decreased due to an increase in the issuer's outstanding shares and voting rights, not through direct transactions.
NASDAQ
CLLS
Cellectis SA
SCHEDULE 13D/A: French State-Backed Entities Clarify Significant Stake in Cellectis S.A. Through Amended SEC Filing
An amended Schedule 13D filing by several French state-backed entities clarifies their beneficial ownership and voting rights in Cellectis S.A., detailing differing percentage calculations under U.S. and French law.
NASDAQ
CLLS
Cellectis SA
SCHEDULE: AstraZeneca Increases Stake in Cellectis to 44% Following Convertible Share Acquisition
AstraZeneca and its subsidiary now hold a 44% stake in Cellectis after converting preferred shares, with the ability to resell these shares publicly.